Kamada Ltd.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $8.16
- 52-Week Range
- $6.60 – $9.35
- Market Cap
- $465.90M
- P/E (TTM)
- 21.24
- EPS (TTM)
- 0.38
- Dividend Yield
- 2.11%
Advanced Metrics
- Price/Book
- 1.72
- PEG Ratio
- 0.65
- Return on Equity
- 9.35%
- Return on Assets
- 5.00%
- Gross Margin
- 41.59%
- Operating Margin
- 15.43%
- Profit Margin
- 12.67%
- Current Ratio
- 4.17
- Debt/Equity
- 0.04
- Total Debt
- $11.72M
- Free Cash Flow
- $22.89M
- Revenue Growth
- 10.70%
- Earnings Growth
- 55.60%
- Enterprise Value
- $396.97M
Market Snapshot
About
Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma-derived protein therapeutics and biopharmaceutical products. The company develops, manufactures, and markets specialty pharmaceutical products with a focus on orphan indications and niche markets. Kamada's portfolio includes treatments for rare diseases such as hereditary angioedema, alpha-1 antitrypsin deficiency, and immunodeficiency disorders. The company operates its own plasma fractionation facility and partners with healthcare organizations globally to distribute its products.